Navigation Links
Yeast Model Shows Promise as Alzheimer's Test

A century ago this month, German psychiatrist Alois Alzheimer formally described characteristics of the neurodegenerative disease //which ultimately came to bear his name. While international efforts to learn about Alzheimer's disease and develop treatments have progressed significantly in recent years, a cure remains an elusive goal.

A new research tool developed by Susan Liebman, distinguished university professor of biological sciences at the University of Illinois at Chicago, may ultimately provide a means for treating the earliest stage of Alzheimer's, thereby stemming its progression.

Alzheimer's disease is characterized by the formation of plaques in the brain largely composed of fibers made from a peptide called beta-amyloid, or A-beta, for short. There is abundant evidence to support the hypothesis that accumulation of A-beta peptide triggers the appearance of Alzheimer's. But while earlier research suggested the A-beta fiber caused Alzheimer's, recent research points at much smaller aggregates of the peptide as the culprit.

"We've developed a yeast model system in which A-beta small aggregate formation can be detected," said Liebman. "The system employs a fusion of the human A-beta peptide to a functional yeast protein, called a reporter protein, which is only active in allowing cells to grow on test media if the fusion does not form aggregates."

Liebman said the yeast model system can be used to develop a high throughput assay to screen small molecules to find those that inhibit the A-beta dependent aggregation. "We'll screen a library of drugs and compounds, looking for ones that allow our yeast with the reporter protein to grow."

She said after the assay conditions are perfected, the screen will be ready for an automated process that will allow for fast testing of many compounds. Medicinal chemists would then study the structures of compounds that pass the screen and design compounds that en hance the activity without being toxic. Animal and human trials would follow.

"One promising, emerging approach for treatment of Alzheimer's disease is to prevent these smaller aggregates from forming," said Liebman. "Disruption of these small aggregates rather than the larger fibers seems prudent since inhibition of A-beta fiber formation might cause the smaller aggregate species to accumulate, and since inhibiting smaller aggregate formation should also prevent the initial formation of the fibers."

Source-Newswise
'"/>




Related medicine news :

1. Yeast Genome Unravels Genes Critical For Maintaining DNA Integrity
2. Chinese Red Yeast Rice Lowers Lipid Levels
3. From a Lowly Yeast, Researchers Divine a Clue to Human Disease
4. Primitive Yeast Yields Secrets Of Human Cholesterol And Drug Metabolism
5. Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find
6. Researchers Develop Mouse Model Of Brain Tumor
7. New Model for understanding Tumor Metastasis
8. Mathematical Model Can Now Help Predict Asthma Risk
9. Model Kate Moss - Re-Birth After Humiliation
10. Womens Self-Esteem Not Lowered By Seeing Ultra Thin Models
11. India Can Become A Role Model In Combating HIV Infections
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... ... August 23, 2017 , ... Based on ... safety and efficacy of HBOT in treating and helping to heal addictions and ... research showing the similarities of the wounds to the brain from traumatic brain ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... healthcare industry, made the 2017 Inc. 5000 with a three-year sales growth ... nation’s fastest-growing private companies and comprises the most comprehensive look at America’s independent ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... the American Academy of Orthopaedic Surgeons , points out that therapeutic modalities ... from pain or injury. According to the report, a wider scope of physical ...
(Date:8/22/2017)... ... August 22, 2017 , ... The old adage ... as simple as eating healthy foods. But this well-known piece of nutrition advice ... or breaking apart carbohydrates—depends not only on properties of the food but also ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
Breaking Medicine Technology: